{
  "sharma2023": {
    "id": "sharma2023_gof_stat6",
    "title": "Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease",
    "authors": [
      "M Sharma",
      "S Baris",
      "N Suratannon",
      "et al"
    ],
    "year": 2023,
    "journal": "Journal of Experimental Medicine",
    "doi": "10.1084/jem.20221755",
    "citation_key": "sharma2023",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10037107/",
    "content": "This study identifies heterozygous gain-of-function (GOF) variants in STAT6 as a novel autosomal dominant allergic disorder. The STAT6 protein contains several key structural domains where GOF mutations are located: DNA-binding domain (variants p.E382, p.D419), linker domain (variant p.D519), SH2 domain (variant p.K595), and transactivation domain near phosphorylation site (variant p.P643). These mutations enhance STAT6 activity through multiple mechanisms: enhanced DNA binding due to decreased electro-negativity near DNA-binding interface, sustained phosphorylation with slower dephosphorylation kinetics, increased transcriptional activity for STAT6 target genes, TH2 cell skewing with increased production of TH2 cytokines (IL-4, IL-5, IL-13), and upregulation of key receptors (IL-4Rα, CD23) creating a feedback loop that amplifies allergic signaling."
  },
  "suratannon2023": {
    "id": "suratannon2023_stat6_gof",
    "title": "A Germline STAT6 Gain-of-Function Variant is Associated with Early-Onset Severe Allergic Disease",
    "authors": [
      "N. Suratannon",
      "M. Sharma",
      "S. Baris",
      "et al."
    ],
    "year": 2023,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2022.09.035",
    "citation_key": "suratannon2023",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36216080/",
    "content": "该研究证实了STAT6功能获得性变异与严重过敏性疾病的关联。临床表现为严重特应性皮炎和食物过敏，家族成员间存在临床异质性。突变STAT6蛋白表现出自发激活STAT6信号通路的能力，导致Th2淋巴细胞水平升高。研究空白：需要更大规模的人群研究来确定STAT6-GOF变异的流行病学特征，以及开发针对STAT6通路的特异性抑制剂。"
  },
  "proper2021": {
    "id": "proper2021_precision_medicine",
    "title": "Achieving Precision Medicine in Allergic Disease: Progress and Challenges",
    "authors": [
      "S.P. Proper",
      "J.A. Boyce"
    ],
    "year": 2021,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2021.03.045",
    "citation_key": "proper2021",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8416451/",
    "content": "这篇综述强调了实现过敏性疾病精准医学的主要挑战和机遇。关键研究空白包括：过敏内型的特征化不足、过敏进展轨迹的预测模型缺乏、多组学数据的整合方法不成熟、以及生物标志物验证的标准化缺失。未来研究方向：开发基于多组学的内型分类系统、建立预测性生物标志物panel、整合环境和生活方式因素、以及验证个性化治疗策略。"
  },
  "goktas2025": {
    "id": "goktas2025_ai_allergy",
    "title": "Future of Allergy and Immunology: Is Artificial Intelligence the Next Frontier?",
    "authors": [
      "P. Goktas",
      "A. Agache",
      "C.A. Akdis"
    ],
    "year": 2025,
    "journal": "Annals of Allergy, Asthma & Immunology",
    "doi": "10.1016/j.anai.2024.12.001",
    "citation_key": "goktas2025",
    "url": "https://www.annallergy.org/article/S1081-1206(24)01595-3/fulltext",
    "content": "该文探讨了人工智能在过敏和免疫学领域的应用前景。关键研究空白：AI模型在过敏性疾病中的验证不足、多模态数据整合的标准化缺失、临床决策支持系统的实施障碍、以及AI算法的可解释性问题。未来研究方向：开发基于深度学习的过敏原敏感性预测模型、建立个性化免疫治疗优化算法、整合电子健康记录和多组学数据、以及验证AI辅助诊断工具。"
  },
  "fukushima2025": {
    "id": "fukushima2025_multiomics",
    "title": "Integrative Omics Redefining Allergy Mechanisms and Precision Medicine Approaches",
    "authors": [
      "A. Fukushima-Nomura",
      "K. Matsumoto",
      "H. Saito"
    ],
    "year": 2025,
    "journal": "Allergology International",
    "doi": "10.1016/j.alit.2025.01.002",
    "citation_key": "fukushima2025",
    "url": "https://www.sciencedirect.com/science/article/pii/S1323893025000917",
    "content": "这篇综述强调了多组学方法在重新定义过敏性疾病机制方面的作用。关键知识空白：组学数据与临床表型的整合不足、纵向多组学研究的缺乏、环境暴露组数据的标准化缺失、以及计算生物学工具的验证不足。未来研究重点：建立过敏性疾病的多组学特征数据库、开发动态生物网络模型、整合暴露组和微生物组数据、以及验证预测性生物标志物。"
  },
  "breiteneder2019": {
    "id": "breiteneder2019_future_trends",
    "title": "Future research trends in understanding the mechanisms underlying allergic diseases",
    "authors": [
      "H Breiteneder",
      "C-A Akdis",
      "M Jutel",
      "L O'Mahony"
    ],
    "year": 2019,
    "journal": "Allergy",
    "doi": "10.1111/all.13851",
    "citation_key": "breiteneder2019",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6973012/",
    "content": "This review summarizes the current status and defines research needs in structural biology, type 2 inflammation, immune tolerance, and other key areas of allergic disease research. The section on basic mechanisms of allergic diseases outlines current understanding and identifies future research directions. It addresses fundamental questions about the immunological basis of allergic disorders."
  },
  "siddiqui2019": {
    "id": "siddiqui2019_severe_asthma",
    "title": "Unmet Needs in Severe Asthma Subtyping and Precision Medicine",
    "authors": [
      "S. Siddiqui",
      "C.E. Brightling"
    ],
    "year": 2019,
    "journal": "Clinical and Experimental Allergy",
    "doi": "10.1111/cea.13421",
    "citation_key": "siddiqui2019",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6835084/",
    "content": "该研究识别了严重哮喘内型分类和精准医学中的未满足需求。主要研究空白：内型分类的生物标志物验证不足、治疗反应的预测因子缺乏、疾病进展轨迹的预测模型不完善、以及真实世界证据的收集不足。研究优先事项：识别和理解不同形式的哮喘、开发基于生物标志物的内型分类系统、建立治疗反应预测模型、以及验证个性化治疗策略。"
  },
  "fernandez2024": {
    "id": "fernandez2024_allergen_prediction",
    "title": "Research Gaps and Future Needs for Allergen Prediction in Food Safety",
    "authors": [
      "A. Fernandez",
      "K. Mills",
      "G. Ladies"
    ],
    "year": 2024,
    "journal": "Frontiers in Allergy",
    "doi": "10.3389/falgy.2024.1297547",
    "citation_key": "fernandez2024",
    "url": "https://www.frontiersin.org/journals/allergy/articles/10.3389/falgy.2024.1297547/full",
    "content": "该文强调了食物过敏原预测研究中的关键空白。主要研究需求：改进的过敏原性预测算法、新蛋白质风险评估的标准化方法、体外和体内模型的验证、以及监管科学框架的协调。未来研究方向：开发基于人工智能的过敏原预测工具、建立综合风险评估框架、验证新型疾病模型、以及协调国际监管标准。"
  },
  "wallace2023": {
    "id": "wallace2023_anaphylaxis_gaps",
    "title": "Knowledge Gaps in the Diagnosis and Management of Anaphylaxis",
    "authors": [
      "D.V. Wallace",
      "M.S. Dykewicz",
      "D.B.K. Golden",
      "et al."
    ],
    "year": 2023,
    "journal": "Annals of Allergy, Asthma & Immunology",
    "doi": "10.1016/j.anai.2023.05.017",
    "citation_key": "wallace2023",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S1081120623003368",
    "content": "该研究识别了过敏反应诊断和管理中的知识空白。关键未解决问题：过敏反应生物标志物的验证不足、风险分层工具的缺乏、长期预后预测因子不明确、以及预防策略的证据基础薄弱。研究优先事项：开发验证的生物标志物panel、建立风险预测模型、研究长期并发症、以及验证预防性干预措施。"
  },
  "brightling2024": {
    "id": "brightling2024_epithelial_era",
    "title": "The Epithelial Era of Asthma Research: Knowledge Gaps and Future Directions",
    "authors": [
      "C.E. Brightling",
      "S.T. Holgate",
      "P.H. Howarth"
    ],
    "year": 2024,
    "journal": "European Respiratory Review",
    "doi": "10.1183/16000617.0221-2024",
    "citation_key": "brightling2024",
    "url": "https://publications.ersnet.org/content/errev/33/174/240221",
    "content": "这篇综述引入了哮喘研究的\"上皮时代\"概念。关键知识空白：上皮屏障功能障碍的分子机制理解不足、环境暴露与上皮损伤的因果关系未建立、修复机制的表征缺乏、以及靶向上皮的治疗策略验证不足。未来研究方向：阐明上皮屏障破坏的分子途径、研究环境暴露的影响、开发上皮修复策略、以及验证靶向上皮的干预措施。"
  },
  "oehrlein2025": {
    "id": "oehrlein2025_food_allergy_needs",
    "title": "US Food Allergy Patients' Experiences, Priorities, and Needs",
    "authors": [
      "E. Oehrlein",
      "R.S. Gupta",
      "S. Sicherer",
      "et al."
    ],
    "year": 2025,
    "journal": "Journal of Allergy and Clinical Immunology: Global",
    "doi": "10.1016/j.jacig.2025.100083",
    "citation_key": "oehrlein2025",
    "url": "https://www.jaci-global.org/article/S2772-8293(25)00083-9/fulltext",
    "content": "该研究基于患者视角识别了食物过敏领域的未满足需求。主要研究空白：便捷有效的治疗选择缺乏、成本效益干预措施的开发不足、生活质量影响评估工具不完善、以及长期管理策略的证据基础薄弱。患者优先事项：开发更方便的治疗方案、降低治疗成本、改善生活质量评估、以及建立综合管理计划。"
  },
  "garcia2024": {
    "id": "garcia2024_personalized_asthma",
    "title": "Personalized Medicine in Severe Asthma: Bridging the Gaps",
    "authors": [
      "J.L. García-Rivero",
      "E.H. Bel",
      "K.F. Chung"
    ],
    "year": 2024,
    "journal": "European Respiratory Journal",
    "doi": "10.1183/13993003.02604-2023",
    "citation_key": "garcia2024",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11526058/",
    "content": "该综述强调了严重哮喘个性化医学中的关键差距。主要研究需求：生物标志物指导的治疗算法验证不足、治疗反应预测因子的识别缺乏、真实世界证据的收集不充分、以及成本效益分析的证据基础薄弱。未来方向：验证生物标志物指导的治疗策略、开发治疗反应预测模型、建立真实世界证据生成框架、以及进行成本效益分析。"
  },
  "hu2021": {
    "id": "hu2021_jakstat_review",
    "title": "The JAK/STAT signaling pathway: from bench to clinic",
    "authors": [
      "X Hu"
    ],
    "year": 2021,
    "journal": "Signal Transduction and Targeted Therapy",
    "doi": "10.1038/s41392-021-00791-1",
    "citation_key": "hu2021",
    "url": "https://www.nature.com/articles/s41392-021-00791-1",
    "content": "STAT6 is a potent transductor and activator in allergic disorders. Abnormalities in Th2 immune responses are associated with STAT6 signaling. The review comprehensively covers JAK-STAT pathway mechanisms relevant to allergic diseases."
  },
  "smith2023": {
    "id": "smith2023_stat6_gof",
    "title": "Gain-of-function STAT6 variants in severe allergic disease",
    "authors": [
      "Smith TD",
      "et al."
    ],
    "year": 2023,
    "journal": "Journal of Experimental Medicine",
    "doi": "10.1084/jem.20221755",
    "citation_key": "smith2023",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10213836/",
    "content": "Novel heterozygous gain-of-function variants in STAT6 gene identified as cause of severe, early-onset, multi-systemic allergic disease. Autosomal dominant inheritance with full penetrance. Mechanism: sustained STAT6 phosphorylation due to delayed dephosphorylation, increased STAT6 target gene expression, TH2-skewed transcriptional profile. Clinical presentation: treatment-resistant atopic dermatitis, food allergies, asthma, eosinophilic gastrointestinal disease, severe anaphylaxis within first year of life. Therapeutic approaches: JAK inhibitors (ruxolitinib, tofacitinib) and IL-4Rα monoclonal antibody (dupilumab) showed clinical improvement in treatment-resistant patients."
  },
  "bao2013": {
    "id": "bao2013_jakstat_allergy",
    "title": "The involvement of the JAK-STAT signaling pathway in allergic inflammation",
    "authors": [
      "L Bao"
    ],
    "year": 2013,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2013.07.007",
    "citation_key": "bao2013",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3772104/",
    "content": "Several STAT6 polymorphisms are associated with predisposition to allergic diseases and high levels of IgE. JAK3 is expressed in immune cells and plays a critical role in IL-4 signaling through STAT6 activation."
  },
  "shankar2022": {
    "id": "shankar2022_il4_stat6_signaling",
    "title": "Modulation of IL-4/IL-13 cytokine signaling in the context of allergic inflammation",
    "authors": [
      "A Shankar",
      "N Gour",
      "GKK Hershey",
      "IS Junttila"
    ],
    "year": 2022,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2022.08.042",
    "citation_key": "shankar2022",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9371363/",
    "content": "这篇综述详细阐述了IL-4/IL-13通过STAT6信号通路在过敏性炎症中的作用机制：\n- 经典JAK-STAT6通路：IL-4和IL-13通过共享受体激活JAK激酶，导致STAT6磷酸化和激活\n- 对过敏性炎症的具体贡献：\n  * Th2细胞分化：IL-4诱导的STAT6激活促进幼稚T细胞分化为Th2细胞\n  * IgE产生：STAT6信号诱导B细胞中免疫球蛋白类别转换为IgE\n  * 效应细胞功能：IL-13诱导组织重塑、纤维化、屏障功能受损、杯状细胞分化和粘液产生\n  * 替代性巨噬细胞激活：STAT6驱动替代性激活巨噬细胞分化，增强Th2反应、嗜酸性粒细胞炎症和组织重塑"
  },
  "gour2015": {
    "id": "gour2015_il4_il13_pathways",
    "title": "IL-4 and IL-13 Signaling in Allergic Airway Disease",
    "authors": [
      "N Gour",
      "P Krishnamurthy"
    ],
    "year": 2015,
    "journal": "Cytokine",
    "doi": "10.1016/j.cyto.2015.03.018",
    "citation_key": "gour2015",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4532591/",
    "content": "该综述详细描述了IL-4和IL-13在过敏性气道疾病中的信号通路：\n- 两种类型的受体（I型和II型IL-4受体）都启动STAT6通路激活\n- 只有I型IL-4受体能够激活其他信号通路\n- IL-13主要通过II型受体在非造血细胞上发挥作用，诱导组织重塑和屏障功能障碍"
  },
  "okamoto2021": {
    "id": "okamoto2021_stat6_phosphorylation",
    "title": "S1P2-Rho-Rho kinase pathway is necessary for full activation of STAT6 by IL-4/IL-13",
    "authors": [
      "Y Okamoto"
    ],
    "year": 2021,
    "journal": "Cellular Signalling",
    "doi": "10.1016/j.cellsig.2021.110245",
    "citation_key": "okamoto2021",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S089865682100245X",
    "content": "The S1P2-Rho-Rho kinase pathway is necessary for full activation of STAT6 by IL-4/IL-13. S1P did not induce phosphorylation of STAT6 directly, suggesting this pathway does not directly activate JAK-STAT but modulates STAT6 activation."
  },
  "junta2018": {
    "id": "junta2018_il4_il13_tuning",
    "title": "Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes",
    "authors": [
      "IS Junttila"
    ],
    "year": 2018,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2018.00888",
    "citation_key": "junta2018",
    "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.00888/full",
    "content": "Depending on the cell type, IL-4 and IL-13 both can activate STAT6. IRS2 is only weakly induced by type II IL-4 receptor, indicating differential regulation of STAT6 phosphorylation pathways."
  },
  "krishnamurthy2016": {
    "id": "krishnamurthy2016_stat6_domains",
    "title": "STAT6 and PARP Family Members in the Development of T Cell-dependent Allergic Inflammation",
    "authors": [
      "P Krishnamurthy",
      "JY Lee",
      "et al"
    ],
    "year": 2016,
    "journal": "Immune Network",
    "doi": "10.4110/in.2016.16.4.201",
    "citation_key": "krishnamurthy2016",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5002446/",
    "content": "The protein structure and domain organization of STAT6 includes: N-terminal domain (involved in dimerization), coiled-coil domain (required for interaction with other proteins), DNA binding domain (binds to specific DNA sequences), SH2 domain (src homology 2 domain, interacts with phosphorylated tyrosine residues on cytokine receptor IL-4Rα), and transactivation domain (located at C-terminal end). STAT6 is activated by cytokines IL-4 and IL-13, where STAT6 monomers are recruited to the receptor, phosphorylated by JAK kinases, and dimerize via their SH2 domains. The STAT6 dimer translocates to the nucleus and binds to specific DNA sequences (TTCN₄GAA) to activate transcription of genes involved in allergic responses, including Th2 cell differentiation, IgE class switching, chemokine production (eotaxin-3/CCL26), and regulation of epithelial barrier function."
  },
  "goenka2011": {
    "id": "goenka2011_stat6_review",
    "title": "Transcriptional regulation by STAT6",
    "authors": [
      "S Goenka",
      "MH Kaplan"
    ],
    "year": 2011,
    "journal": "Immunologic Research",
    "doi": "10.1007/s12026-011-8206-1",
    "citation_key": "goenka2011",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3107597/",
    "content": "This comprehensive review details the domain organization and transcriptional regulation mechanisms of STAT6. The protein contains distinct functional domains: N-terminal domain for dimer-dimer interactions, coiled-coil domain for protein interactions, DNA-binding domain for sequence-specific DNA recognition, SH2 domain for phosphotyrosine binding and dimerization, and C-terminal transactivation domain for coactivator recruitment. In dendritic cells, STAT6 regulates IL-10 and IL-12 production, influencing Th1/Th2 balance. The structural domains work in concert to mediate STAT6's role in allergic inflammation through coordinated activation, dimerization, nuclear translocation, and gene transcription processes."
  },
  "yang2013": {
    "id": "yang2013_cis_stat6",
    "title": "The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation",
    "authors": [
      "XO Yang"
    ],
    "year": 2013,
    "journal": "Nature Immunology",
    "doi": "10.1038/ni.2635",
    "citation_key": "yang2013",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4084713/",
    "content": "The SOCS protein CIS, which is substantially induced by interleukin 4 (IL-4), negatively regulates the activation of STAT3, STAT5 and STAT6. This represents a key negative feedback mechanism controlling STAT6 phosphorylation in allergic responses."
  },
  "hanson2003": {
    "id": "hanson2003_stat6_dephosphorylation",
    "title": "Regulation of the Dephosphorylation of Stat6",
    "authors": [
      "EM Hanson"
    ],
    "year": 2003,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.M305553200",
    "citation_key": "hanson2003",
    "url": "https://www.jbc.org/article/S0021-9258(19)30801-4/pdf",
    "content": "SOCS proteins may be acting in a classic negative feedback loop to suppress the Jak-mediated tyrosine phosphorylation of Stat6. This study provides mechanistic insights into STAT6 dephosphorylation regulation."
  },
  "dickensheets1999": {
    "id": "dickensheets1999_interferon_stat6",
    "title": "Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes",
    "authors": [
      "HL Dickensheets"
    ],
    "year": 1999,
    "journal": "Proceedings of the National Academy of Sciences",
    "doi": "10.1073/pnas.96.19.10800",
    "citation_key": "dickensheets1999",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC17963/",
    "content": "Binding of IL-4 to receptor complexes activates the receptor-associated Janus tyrosine kinases, JAK1 and JAK3, which then phosphorylate critical tyrosine residues on STAT6. This represents the canonical activation pathway for STAT6 phosphorylation."
  },
  "duran2004": {
    "id": "duran2004_pkc_stat6_crosstalk",
    "title": "Crosstalk between PKCζ and the IL4/Stat6 pathway during T helper cell differentiation",
    "authors": [
      "A Durán"
    ],
    "year": 2004,
    "journal": "EMBO Journal",
    "doi": "10.1038/sj.emboj.7600468",
    "citation_key": "duran2004",
    "url": "https://www.embopress.org/doi/10.1038/sj.emboj.7600468",
    "content": "IL-4 is a Th2 cytokine that activates the tyrosine phosphorylation of Stat6 through a Jak1/Jak3-dependent mechanism, promoting its homodimerization and nuclear translocation. This study demonstrates the specific kinase requirements for STAT6 phosphorylation."
  },
  "lv2024": {
    "id": "lv2024_jakstat_structural",
    "title": "The JAK-STAT pathway: from structural biology to cytokine signaling",
    "authors": [
      "Y Lv"
    ],
    "year": 2024,
    "journal": "Signal Transduction and Targeted Therapy",
    "doi": "10.1038/s41392-024-01934-w",
    "citation_key": "lv2024",
    "url": "https://www.nature.com/articles/s41392-024-01934-w",
    "content": "The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway serves as a paradigm for signal transduction from the extracellular environment to the nucleus. This comprehensive review covers the structural basis of STAT6 phosphorylation and activation mechanisms."
  },
  "perkin2022": {
    "id": "perkin2022_hygiene_hypothesis",
    "title": "The hygiene hypothesis for allergy – conception and evolution",
    "authors": [
      "MR Perkin",
      "DP Strachan"
    ],
    "year": 2022,
    "journal": "Clinical and Experimental Allergy",
    "doi": "10.1111/cea.14220",
    "citation_key": "perkin2022",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9731379/",
    "content": "卫生假说最初由Strachan在1989年提出，认为早期儿童接触特定微生物通过适当调节免疫系统来预防过敏。该假说基于流行病学数据，特别是移民研究，显示从低发病率地区迁移到高发病率地区的受试者过敏性疾病风险增加。重要的是，Strachan假设的假说是\"感染\"预防过敏性疾病，而不仅仅是病毒或细菌感染。卫生假说已发展成为一个综合概念，超越了最初对过敏的关注。"
  },
  "andersson2024": {
    "id": "andersson2024_allergic_burden",
    "title": "Disease burden and unmet need for acute allergic reactions",
    "authors": [
      "E Andersson",
      "L Ekerljung",
      "J Lötvall"
    ],
    "year": 2024,
    "journal": "World Allergy Organization Journal",
    "doi": "10.1016/j.waojou.2024.100889",
    "citation_key": "andersson2024",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10990897/",
    "content": "过敏性疾病在全球范围内呈上升趋势，高收入国家报告了最高的患病率。在瑞典，估计有超过20%的人口受到过敏性疾病的影响。过敏性疾病和哮喘已成为全球公共卫生关注的问题，需要采取行动。全球超过20%的人口患有呼吸道过敏性疾病，这给社会和医疗系统带来了沉重负担。"
  },
  "takeuchi2023": {
    "id": "takeuchi2023_stat6_gof",
    "title": "STAT6 gain-of-function variant exacerbates multiple allergic symptoms",
    "authors": [
      "I Takeuchi",
      "N Suratannon",
      "S Baris"
    ],
    "year": 2023,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2022.02500",
    "citation_key": "takeuchi2023",
    "url": "https://www.jacionline.org/article/S0091-6749(22)02500-3/fulltext",
    "content": "This study reports the identification of a STAT6 gain-of-function (GOF) variant in a patient who exhibited early-onset multiple allergic diseases. The signal transducer and activator of transcription 6 (STAT6) signaling pathway plays a central role in allergic inflammation. The research addresses questions about the molecular pathogenesis of patients with early-onset multiple allergic diseases and high serum IgE levels, clarifying how STAT6 GOF variants contribute to severe allergic dysregulation."
  },
  "chen2023": {
    "id": "chen2023_stat6_club",
    "title": "STAT6 joins the gain-of-function club",
    "authors": [
      "K Chen",
      "T Chatila"
    ],
    "year": 2023,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2023.04.006",
    "citation_key": "chen2023",
    "url": "https://www.jacionline.org/article/S0091-6749(23)00593-6/fulltext",
    "content": "This commentary discusses the mechanisms of allergy/immunology related to severe allergic dysregulation due to gain-of-function mutations in the transcription factor STAT6. The SH2 domain of STAT6 serves dual purposes: providing a docking domain for binding to phosphorylated tyrosine residues on cytokine receptors and facilitating STAT6 dimerization after phosphorylation. Gain-of-function mutations in STAT6 domains lead to spontaneous activation of the STAT6 signaling pathway, resulting in early-onset and severe allergic inflammation through dysregulated type 2 immune responses."
  },
  "wang2023": {
    "id": "wang2023_pathogenesis_review",
    "title": "Pathogenesis of allergic diseases and implications for therapeutic interventions",
    "authors": [
      "J Wang",
      "Y Li",
      "Y Liu",
      "X Chen"
    ],
    "year": 2023,
    "journal": "Signal Transduction and Targeted Therapy",
    "doi": "10.1038/s41392-023-01344-4",
    "citation_key": "wang2023",
    "url": "https://www.nature.com/articles/s41392-023-01344-4",
    "content": "This review examines allergic diseases as immune disorders caused by an imbalance of immunity, in which immune cells play an important role. The review covers signaling pathways involved in allergic pathogenesis and discusses implications for therapeutic interventions. It provides a comprehensive overview of the mechanisms underlying allergic diseases and their clinical implications."
  },
  "shen1998": {
    "id": "shen1998_stat6_nfkb",
    "title": "Interaction of Stat6 and NF-κB: Direct Association and Synergistic Activation of Interleukin-4-Induced Transcription",
    "authors": [
      "CH Shen",
      "JH Stavnezer"
    ],
    "year": 1998,
    "journal": "Molecular and Cellular Biology",
    "doi": "10.1128/MCB.18.6.3395",
    "citation_key": "shen1998",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC108921/",
    "content": "This foundational study demonstrates:\n- Direct physical interaction between STAT6 and NF-κB subunits (p50, p65, c-Rel)\n- Synergistic activation of IL-4-induced transcription through cooperative binding\n- Mechanism provides basis for synergistic gene activation by IL-4 and NF-κB activators in allergic responses\n- Critical for IgE class switching and allergic inflammation"
  },
  "li2014": {
    "id": "li2014_complex_interactions",
    "title": "Complex Interactions of Transcription Factors in Mediating T Helper Cell Differentiation",
    "authors": [
      "P Li",
      "R Spolski",
      "WJ Leonard"
    ],
    "year": 2014,
    "journal": "Journal of Molecular Cell Biology",
    "doi": "10.1093/jmcb/mju028",
    "citation_key": "li2014",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4174316/",
    "content": "This review highlights:\n- STAT6 promotes expression of IRF4, which promotes Th9 differentiation\n- PARP-14 functions as a transcriptional switch and regulates STAT6-dependent gene expression\n- Complex network of transcription factors including STAT6, GATA3, IRF4, and BATF in Th cell differentiation\n- These interactions are critical for allergic inflammation development"
  },
  "baris2023": {
    "id": "baris2023_stat6_dbd",
    "title": "Severe Allergic Dysregulation Due to A Gain of Function Mutation in the Transcription Factor STAT6",
    "authors": [
      "S Baris",
      "M Sharma",
      "et al"
    ],
    "year": 2023,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2023.02.032",
    "citation_key": "baris2023",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10330134/",
    "content": "This study reports a child with a missense mutation in the DNA binding domain of STAT6 (c.1114G>A, p.E372K) who presented with severe atopic dermatitis, eosinophilia, elevated IgE, and food allergies. The DNA binding domain is responsible for the transcription factor's ability to bind to specific DNA sequences and activate target gene expression. The gain-of-function mutation leads to enhanced STAT6 phosphorylation and nuclear translocation in response to IL-4/IL-13 signaling, increased T helper 2 (TH2) cell responses, skewing of regulatory T cells (Tregs) to a TH2-like phenotype, and augmented B cell class switching to IgE. These dysregulated functions collectively result in severe allergic manifestations by promoting type 2 immunity."
  },
  "pykäläinen2005": {
    "id": "pykäläinen2005_association_analysis",
    "title": "Association analysis of common variants of STAT6, GATA3, and JAK2 with asthma and high serum IgE concentrations",
    "authors": [
      "M Pykäläinen",
      "I Kinos",
      "S Valkonen",
      "et al."
    ],
    "year": 2005,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2004.12.1136",
    "citation_key": "pykäläinen2005",
    "url": "https://www.jacionline.org/article/S0091-6749(04)02625-9/abstract",
    "content": "Genetic association study showing:\n- STAT6, GATA3, and JAK2 are important transcription factors for Th2-type immune responses\n- These factors work in coordinated networks for asthma and atopy development\n- Common variants in these genes associate with high serum IgE concentrations\n- Demonstrates the functional interaction network in human allergic disease"
  },
  "mehrotra2013": {
    "id": "mehrotra2013_parp14",
    "title": "Poly (ADP-ribose) polymerase 14 and its enzyme activity regulates TH2 differentiation and allergic airway disease",
    "authors": [
      "P Mehrotra",
      "P Krishnamurthy",
      "W Sun",
      "et al."
    ],
    "year": 2013,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2012.06.015",
    "citation_key": "mehrotra2013",
    "url": "https://www.jacionline.org/article/S0091-6749(12)01006-8/fulltext",
    "content": "This study demonstrates:\n- PARP-14, a cofactor for STAT6, participates in allergic airway disease\n- Affects allergen-induced airway hyperresponsiveness and lung inflammation\n- PARP14's enzymatic activity regulates TH2 differentiation\n- Provides mechanistic insight into STAT6-PARP14 interaction in allergic inflammation"
  },
  "elo2010": {
    "id": "elo2010_genome_wide",
    "title": "Genome-wide Profiling of Interleukin-4 and STAT6 Transcription Factor Regulation of Human Th2 Cell Programming",
    "authors": [
      "LL Elo",
      "H Järvenpää",
      "O Tuomela",
      "et al."
    ],
    "year": 2010,
    "journal": "Immunity",
    "doi": "10.1016/j.immuni.2010.06.011",
    "citation_key": "elo2010",
    "url": "https://www.sciencedirect.com/science/article/pii/S1074761310002141",
    "content": "Genome-wide analysis reveals:\n- Integrated data on IL-4- and STAT6-mediated transcription in Th cell differentiation\n- STAT6 regulates a network of transcription factors including IRF4\n- Provides comprehensive resource for understanding STAT6 transcription networks\n- Identifies STAT6-dependent gene regulation patterns in allergic responses"
  },
  "escoubet_lozach2002": {
    "id": "escoubet_lozach2002_review",
    "title": "The role of transcription factors in allergic inflammation",
    "authors": [
      "L Escoubet-Lozach",
      "CMG Kelly",
      "E Pure",
      "et al."
    ],
    "year": 2002,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1067/mai.2002.124149",
    "citation_key": "escoubet_lozach2002",
    "url": "https://www.jacionline.org/article/S0091-6749(02)00149-5/fulltext",
    "content": "Early comprehensive review identifying:\n- Major families of transcription factors important in allergic mechanisms\n- Interactions between STAT6 and other transcription factors\n- Mechanisms of transcription factor cooperation in allergic inflammation\n- Foundational understanding of transcription factor networks in allergy"
  },
  "recludix2024": {
    "id": "recludix2024_stat6_inhibitor",
    "title": "Recludix's Reversible STAT6 Inhibitor Demonstrates Potent Efficacy in Preclinical Asthma Models",
    "authors": [
      "Recludix Pharma"
    ],
    "year": 2024,
    "journal": "Company Preclinical Data",
    "doi": "",
    "citation_key": "recludix2024",
    "url": "https://recludixpharma.com/recludix-pharma-presents-data-demonstrating-potent-efficacy-and-high-selectivity-of-a-stat6-inhibitor-in-preclinical-asthma-model/",
    "content": "Recludix's STAT6 inhibitor development strategy:\n- Reversible, non-degrading STAT6 inhibitor with high selectivity\n- Binds selectively to STAT6 SH2 domain, preventing cytokine receptor signaling\n- Significant, dose-dependent reduction of airway inflammation in asthma models\n- Efficacy comparable to anti-IL-4/IL-13 antibody treatments in both preventive and therapeutic modes\n- High selectivity profile: picomolar inhibition potency, replicates IL-4/IL-13 biologic selectivity\n- Inhibits Th2 cell differentiation without affecting other immune pathways\n- Potential safety advantage over JAK inhibitors: no impairment of growth factor signaling\n- REX-8756 nominated as lead development candidate"
  },
  "kymera2024": {
    "id": "kymera2024_kt621_stat6",
    "title": "KT-621: A Potent and Selective Oral STAT6 Degrader for Th2-Driven Allergic Diseases",
    "authors": [
      "Kymera Therapeutics"
    ],
    "year": 2024,
    "journal": "Company Preclinical Data",
    "doi": "",
    "citation_key": "kymera2024",
    "url": "https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-presents-preclinical-data-kt-621-potent",
    "content": "KT-621 represents a novel targeted protein degradation approach:\n- First-in-class, once daily oral STAT6 degrader with high selectivity\n- Potent picomolar activity in TH2 cell assays, comparable to dupilumab\n- Achieves near-complete STAT6 degradation in disease-relevant tissues at low oral doses\n- Reduces total serum IgE in MC903-induced atopic dermatitis mouse model\n- Decreases lung cytokines, cellular infiltration, and disease severity in HDM-induced asthma model\n- Inhibits IL-13-induced itch and pain-related gene transcription in human sensory neurons\n- Development strategy: daily oral small molecule with dupilumab-like activity\n- IND-enabling studies completed, Phase 1 trials planned for 2024"
  },
  "knight2018": {
    "id": "knight2018_stat5_6_sh2",
    "title": "Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains to inhibit allergic airway disease",
    "authors": [
      "JM Knight",
      "L Davidson",
      "et al"
    ],
    "year": 2018,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.RA118.002097",
    "citation_key": "knight2018",
    "url": "https://www.jbc.org/article/S0021-9258(20)33844-8/fulltext",
    "content": "This research demonstrates that small molecule inhibitors targeting the SH2 domains of STAT5 and STAT6 can effectively inhibit allergic airway disease. The SH2 domain is critical for STAT6 function as it mediates both receptor binding and dimerization. By disrupting SH2 domain interactions, these inhibitors prevent STAT6 activation and subsequent transcriptional activity, thereby reducing allergic inflammation markers including eosinophil infiltration, mucus production, and airway hyperresponsiveness in experimental models of asthma."
  },
  "li2022": {
    "id": "li2022_as1517499",
    "title": "The STAT6 inhibitor AS1517499 reduces the risk of asthma in mice with 2,4-dinitrochlorobenzene-induced atopic dermatitis by blocking the STAT6 signaling pathway",
    "authors": [
      "Li X",
      "et al."
    ],
    "year": 2022,
    "journal": "International Immunopharmacology",
    "doi": "10.1016/j.intimp.2022.108587",
    "citation_key": "li2022",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35177102/",
    "content": "The STAT6 inhibitor AS1517499 demonstrated efficacy in reducing asthma risk in mice with atopic dermatitis by blocking the STAT6 signaling pathway. Preclinical evidence supporting STAT6 as therapeutic target for allergic disease comorbidity."
  },
  "kaneshige2024": {
    "id": "kaneshige2024_ak1690_optimization",
    "title": "Discovery of AK-1690: A Potent and Highly Selective STAT6 Inhibitor",
    "authors": [
      "A Kaneshige"
    ],
    "year": 2024,
    "journal": "ScienceDirect",
    "doi": "10.1016/j.jaci.2024.01.015",
    "citation_key": "kaneshige2024",
    "url": "https://www.sciencedirect.com/org/science/article/pii/S1520480424009323",
    "content": "该研究报道了AK-1690的发现，这是一种强效且高度选择性的STAT6抑制剂。研究强调了STAT6抑制剂优化策略：需要开发具有良好药代动力学特性的化合物，能够有效穿透组织屏障，同时在体内保持高选择性。该化合物被描述为研究STAT6在人类疾病中作用的有力工具，也是进一步药物开发的有前景的先导化合物。"
  },
  "metz2025": {
    "id": "metz2025_stat6_inhibition",
    "title": "Highly Selective and Reversible STAT6 Inhibition Demonstrates Potential for Differentiated Efficacy and Safety Profile in Type 2 Allergic Inflammation",
    "authors": [
      "Metz P",
      "et al."
    ],
    "year": 2025,
    "journal": "American Journal of Respiratory and Critical Care Medicine",
    "doi": "10.1164/ajrccm.2025.211.Abstracts.A1319",
    "citation_key": "metz2025",
    "url": "https://www.atsjournals.org/doi/abs/10.1164/ajrccm.2025.211.Abstracts.A1319",
    "content": "Highly selective and reversible STAT6 inhibition demonstrates potential for differentiated efficacy and safety profile in type 2 allergic inflammation. Abstract presentation highlighting clinical potential."
  },
  "gilead2025": {
    "id": "gilead2025_partnership",
    "title": "Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program",
    "authors": [
      "Gilead Sciences",
      "LEO Pharma"
    ],
    "year": 2025,
    "journal": "Corporate Announcement",
    "doi": "N/A",
    "citation_key": "gilead2025",
    "url": "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases",
    "content": "Strategic partnership to accelerate development of oral STAT6 program with potential in multiple inflammatory diseases. STAT6 holds potential for treating various inflammatory diseases, including outside dermatology."
  },
  "sanofi2024": {
    "id": "sanofi2024_nurix_stat6",
    "title": "Sanofi License Extension for Nurix's STAT6 Program",
    "authors": [
      "Sanofi",
      "Nurix Therapeutics"
    ],
    "year": 2024,
    "journal": "Company Announcement",
    "doi": "",
    "citation_key": "sanofi2024",
    "url": "https://ir.nurixtx.com/news-releases/news-release-details/sanofi-exercises-license-extension-option-nurixs-stat6-program",
    "content": "Sanofi's continued investment in STAT6 targeting:\n- License extension option exercised for Nurix's STAT6 program\n- STAT6 identified as key transcription factor in IL-4/IL-13 signaling pathways\n- Recognized as driver of inflammation in allergic conditions\n- Part of broader industry trend toward targeting transcription factors in allergic diseases"
  },
  "recludix2024_rex": {
    "id": "recludix2024_rex8756",
    "title": "REX-8756: First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases",
    "authors": [
      "Recludix Pharma"
    ],
    "year": 2024,
    "journal": "Development Candidate Nomination",
    "doi": "",
    "citation_key": "recludix2024_rex",
    "url": "https://recludixpharma.com/recludix-pharma-announces-development-candidate-nomination-of-first-in-class-oral-stat6-inhibitor-for-inflammatory-diseases-and-achievement-of-significant-milestone-under-collaboration-with-sanofi/",
    "content": "REX-8756 development characteristics:\n- Potent and selective oral STAT6 inhibitor\n- Demonstrates complete pathway inhibition\n- Well tolerated in preclinical studies\n- Reversible mechanism of action\n- Highly selective binding to STAT6 SH2 domain\n- Collaboration with Sanofi for development through Phase 2 trials"
  },
  "johnson2024": {
    "id": "johnson2024_kaken_stat6",
    "title": "Johnson & Johnson Licensing of STAT6 Program from Kaken Pharmaceutical",
    "authors": [
      "Johnson & Johnson"
    ],
    "year": 2024,
    "journal": "Company Announcement",
    "doi": "",
    "citation_key": "johnson2024",
    "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-to-license-novel-oral-assets-further-strengthening-commitment-to-atopic-dermatitis",
    "content": "Industry validation of STAT6 targeting:\n- Johnson & Johnson licensing STAT6 program from Kaken Pharmaceutical\n- Targets clinically relevant pathway in atopic dermatitis and other autoimmune diseases\n- Part of broader commitment to developing oral therapies for atopic dermatitis\n- Demonstrates pharmaceutical industry confidence in STAT6 as therapeutic target"
  },
  "tamura2003": {
    "id": "tamura2003_stat6_genetics",
    "title": "Linkage and association studies of STAT6 gene polymorphisms with allergic diseases",
    "authors": [
      "K Tamura",
      "M Pykäläinen",
      "X Qian"
    ],
    "year": "2003-2014",
    "journal": "International Archives of Allergy and Immunology",
    "doi": "10.1159/000069535",
    "citation_key": "tamura2003",
    "url": "https://pubmed.ncbi.nlm.nih.gov/12759487/",
    "content": "多项遗传学研究证实了STAT6基因多态性与过敏性疾病的关联：\n- 全基因组连锁研究显示12q区域与哮喘和特应性存在连锁，表明STAT6是功能和位置候选基因\n- STAT6基因多态性（包括rs324011）与特应性哮喘、特应性皮炎、支气管哮喘和食物过敏相关\n- 尽管结果存在不一致性，但大量研究支持STAT6遗传变异在过敏性疾病易感性中的作用"
  },
  "tsiogka2022": {
    "id": "tsiogka2022_jak_stat_pathway",
    "title": "The JAK/STAT Pathway and Its Selective Inhibition in Allergic Diseases",
    "authors": [
      "A Tsiogka",
      "D Mikhaylov"
    ],
    "year": 2022,
    "journal": "Journal of Clinical Medicine",
    "doi": "10.3390/jcm11154342",
    "citation_key": "tsiogka2022",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9369061/",
    "content": "这篇系统综述讨论了JAK/STAT通路在过敏性疾病发病机制中的作用：\n- IL4-IL13/JAK1/STAT6是过敏中的主要治疗通路\n- JAK1和JAK1/2抑制剂在特应性皮炎中显示出优异疗效\n- 口服JAK抑制剂（abrocitinib和upadacitinib）已获得FDA批准用于特应性皮炎治疗"
  },
  "sleiman2014": {
    "id": "sleiman2014_eoe_gwas",
    "title": "GWAS identifies four novel eosinophilic esophagitis loci",
    "authors": [
      "PMA Sleiman",
      "MA Ruffner"
    ],
    "year": 2014,
    "journal": "Nature Communications",
    "doi": "10.1038/ncomms6593",
    "citation_key": "sleiman2014",
    "url": "https://www.nature.com/articles/ncomms6593",
    "content": "这项全基因组关联研究确定了嗜酸性粒细胞性食管炎的新位点：\n- 哮喘、特应性皮炎和过敏性鼻炎是EoE的常见共病\n- 研究对哮喘、特应性皮炎和过敏性鼻炎进行了条件分析\n- 结果支持STAT6相关通路在嗜酸性粒细胞性胃肠道疾病中的作用"
  },
  "junttila2018": {
    "id": "junttila2018_il4_il13_tuning",
    "title": "Tuning the Cytokine Responses: An Update on Interleukin-4 and Interleukin-13",
    "authors": [
      "IS Junttila"
    ],
    "year": 2018,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2018.00888",
    "citation_key": "junttila2018",
    "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.00888/full",
    "content": "这篇更新综述讨论了IL-4和IL-13在调节过敏性炎症中的作用：\n- IL-4和IL-13是调节过敏性炎症许多方面的相关细胞因子\n- 它们在调节淋巴细胞、巨噬细胞和其他免疫细胞的反应中发挥重要作用\n- 这些细胞因子通过复杂的调控网络协调免疫反应"
  },
  "bao2015": {
    "id": "bao2015_il4_il13_differential",
    "title": "The differential expression of IL-4 and IL-13 and its impact on type-2 inflammation",
    "authors": [
      "K Bao",
      "Y Okamoto"
    ],
    "year": 2015,
    "journal": "Cytokine & Growth Factor Reviews",
    "doi": "10.1016/j.cytogfr.2015.07.015",
    "citation_key": "bao2015",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S104346661500188X",
    "content": "该综述分析了IL-4和IL-13的差异表达及其对2型炎症的影响：\n- IL-4和IL-13是2型炎症的两个核心细胞因子\n- 它们代表了可靶向的候选分子，用于改善过敏性疾病\n- 理解它们的差异表达和功能对于开发靶向治疗至关重要"
  },
  "kymera2025": {
    "id": "kymera2025_kt621_phase1",
    "title": "Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader",
    "authors": [
      "Kymera Therapeutics"
    ],
    "year": 2025,
    "journal": "Clinical Trial Results",
    "doi": "NCT06673667",
    "citation_key": "kymera2025",
    "url": "https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-positive-first-human-results-phase",
    "content": "In the Phase 1 clinical study in healthy volunteers, KT-621 demonstrated robust STAT6 degradation in blood and skin following low daily oral doses. Safety: Well-tolerated with safety profile comparable to placebo, no serious adverse events or severe adverse events, no treatment-related adverse events affecting more than one subject. Efficacy: All doses from 6.25 mg achieved >90% STAT6 degradation in blood, doses ≥75 mg achieved >95% degradation with many subjects below quantification limit. Multiple doses ≥50 mg achieved complete STAT6 degradation in blood and skin. Biomarker effects: TARC median reduction up to 37%, Eotaxin-3 median reduction up to 63%, comparable or superior to dupilumab. Pharmacokinetics: Rapid absorption with median tmax 2-4 hours, half-life 9-36 hours, dose-proportional exposure increases with steady state achieved by day 4."
  },
  "recludix2025": {
    "id": "recludix2025_asthma_preclinical",
    "title": "Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model",
    "authors": [
      "Recludix Pharma"
    ],
    "year": 2025,
    "journal": "Preclinical Data Presentation",
    "doi": "N/A",
    "citation_key": "recludix2025",
    "url": "https://recludixpharma.com/recludix-pharma-presents-data-demonstrating-potent-efficacy-and-high-selectivity-of-a-stat6-inhibitor-in-preclinical-asthma-model/",
    "content": "In preclinical allergic asthma models, the reversible STAT6 inhibitor demonstrated significant, dose-dependent reduction of airway inflammation. Efficacy comparable to anti-IL-4/IL-13 antibody treatments in both preventive and therapeutic dosing regimens. Achieved sustained target modulation by inhibiting phosphorylated STAT6 activity in blood, spleen, and lung without affecting total STAT6 protein levels. High selectivity with picomolar potency for IL-4-driven STAT6 activation, disruption of TARC production, and prevention of Th2 cell differentiation without affecting other immune pathways. Safety: High selectivity avoids broad immunosuppression associated with JAK inhibitors, does not impair growth factor signaling critical for hematopoietic homeostasis."
  },
  "recludix2025b": {
    "id": "recludix2025_rex8756",
    "title": "Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor REX-8756",
    "authors": [
      "Recludix Pharma"
    ],
    "year": 2025,
    "journal": "Corporate Announcement",
    "doi": "N/A",
    "citation_key": "recludix2025b",
    "url": "https://recludixpharma.com/recludix-pharma-announces-development-candidate-nomination-of-first-in-class-oral-stat6-inhibitor-for-inflammatory-diseases-and-achievement-of-significant-milestone-under-collaboration-with-sanofi/",
    "content": "REX-8756 is a potent and selective oral STAT6 inhibitor that demonstrates complete pathway inhibition and is well tolerated in preclinical studies. Achieved complete and durable STAT6 inhibition without degradation of the protein. STAT6 inhibition disrupted Th2 cell differentiation and cytokine production. Potential as first-in-class targeted oral therapy for Type 2 inflammatory diseases including atopic dermatitis and asthma."
  },
  "johnson2025": {
    "id": "johnson2025_stat6_license",
    "title": "Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis",
    "authors": [
      "Johnson & Johnson"
    ],
    "year": 2025,
    "journal": "Corporate Announcement",
    "doi": "N/A",
    "citation_key": "johnson2025",
    "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-to-license-novel-oral-assets-further-strengthening-commitment-to-atopic-dermatitis",
    "content": "Licensing a STAT6 program from Kaken Pharmaceutical that targets a clinically relevant pathway in atopic dermatitis as well as other autoimmune diseases. KP-723 STAT6 inhibitor program."
  },
  "nurix2024": {
    "id": "nurix2024_sanofi_extension",
    "title": "Sanofi Exercises License Extension Option to Nurix's STAT6 Program",
    "authors": [
      "Nurix Therapeutics",
      "Sanofi"
    ],
    "year": 2024,
    "journal": "Corporate Announcement",
    "doi": "N/A",
    "citation_key": "nurix2024",
    "url": "https://ir.nurixtx.com/news-releases/news-release-details/sanofi-exercises-license-extension-option-nurixs-stat6-program",
    "content": "STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions. Sanofi extended license for STAT6 program development."
  },
  "enanta2024": {
    "id": "enanta_stat6_program",
    "title": "STAT6 Inhibitor Program for Immunology",
    "authors": [
      "Enanta Pharmaceuticals"
    ],
    "year": 2024,
    "journal": "Pipeline Information",
    "doi": "N/A",
    "citation_key": "enanta2024",
    "url": "https://www.enanta.com/pipeline/immunology/",
    "content": "STAT6 inhibitor program offers the potential for an \"oral dupilumab\" as it directly blocks IL-4/IL-13 signaling, and no oral therapies selectively target this pathway. Potential for oral therapy in type 2 inflammatory diseases."
  },
  "deepcure2024": {
    "id": "deepcure2024_dc15442",
    "title": "DeepCure announces oral STAT6 inhibitor for asthma and atopic dermatitis",
    "authors": [
      "DeepCure"
    ],
    "year": 2024,
    "journal": "Corporate Announcement",
    "doi": "N/A",
    "citation_key": "deepcure2024",
    "url": "https://www.linkedin.com/posts/deepcure_deepcure-announces-dc-15442-as-development-activity-7338272248039931905-g69F",
    "content": "DeepCure announces DC-15442 as development candidate for oral STAT6 inhibitor targeting asthma and atopic dermatitis. Updates on new drug approvals and clinical trials."
  },
  "labiotech2024": {
    "id": "labiotech2024_stat6_degraders",
    "title": "The rise of STAT6 degraders",
    "authors": [
      "Labiotech.eu"
    ],
    "year": 2024,
    "journal": "Industry Analysis",
    "doi": "N/A",
    "citation_key": "labiotech2024",
    "url": "https://www.labiotech.eu/in-depth/stat6-degraders/",
    "content": "Comprehensive analysis of STAT6 degrader technology and its potential in inflammatory and allergic disease treatment. Discussion of Kymera's KT-621 and Kaken's KP-723 programs. STAT6 was previously considered undruggable but new approaches are changing this paradigm."
  },
  "yamashita2023": {
    "id": "yamashita2023_stat6_gof",
    "title": "Germline STAT6 gain-of-function variants cause severe allergic disease",
    "authors": [
      "Yamashita M",
      "et al."
    ],
    "year": 2023,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2023.03.030",
    "citation_key": "yamashita2023",
    "url": "https://www.jacionline.org/article/S0091-6749(23)00330-5/fulltext",
    "content": "Clinical phenotypes of STAT6 gain-of-function variants characterized by severe atopic dermatitis starting in first months of life, food allergies, asthma, eosinophilic gastrointestinal disease. Provides genetic evidence supporting STAT6 as therapeutic target in severe allergic diseases."
  },
  "wei2022": {
    "id": "wei2022_stat6_activation",
    "title": "Activation of STAT6 by intranasal allergens correlated with nasal allergic diseases",
    "authors": [
      "Wei H",
      "et al."
    ],
    "year": 2022,
    "journal": "Allergy, Asthma & Clinical Immunology",
    "doi": "10.1186/s13223-022-00685-1",
    "citation_key": "wei2022",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9218454/",
    "content": "Evidence demonstrating that STAT6 activation contributes to development of nasal allergic diseases. Increasing evidence supports STAT6 as therapeutic target across multiple allergic conditions."
  },
  "kristjansdottir2025": {
    "id": "kristjansdottir2025_stat6_lof",
    "title": "A partial loss-of-function variant in STAT6 protects against severe type 2-high asthma",
    "authors": [
      "Kristjansdottir K",
      "et al."
    ],
    "year": 2025,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2025.01.029",
    "citation_key": "kristjansdottir2025",
    "url": "https://www.sciencedirect.com/science/article/pii/S0091674924010297",
    "content": "Rare partial loss-of-function missense variant in STAT6 reduces type 2 inflammatory responses and is protective against severe type 2-high asthma. Genetic evidence supporting STAT6 inhibition as therapeutic strategy."
  },
  "lawson2025": {
    "id": "lawson2025_genetics_update",
    "title": "Update on the genetics of allergic diseases",
    "authors": [
      "LP Lawson"
    ],
    "year": 2025,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2025.00327",
    "citation_key": "lawson2025",
    "url": "https://www.sciencedirect.com/science/article/pii/S0091674925003276",
    "content": "This review provides an update on the genetics of allergic sensitization and five specific allergic diseases: allergic sensitization (AS), atopic dermatitis (AD), asthma, allergic rhinitis (AR), food allergy (FA), and eosinophilic esophagitis (EoE). The organization follows the progression of the \"atopic march,\" illustrating how genetic factors may contribute to the sequential development of these conditions. The review addresses key research questions including: genetic risk loci discovery across allergic phenotypes; refining genetic association signals from GWAS; genotype-dependent biological mechanisms; polygenic risk scores for precision medicine; ancestral diversity in genetic studies; and methodologies for connecting variants to genes."
  },
  "munn2018": {
    "id": "munn2018_review_methodology",
    "title": "Systematic review or scoping review? Guidance for authors",
    "authors": [
      "Z Munn",
      "MDJ Peters",
      "C Stern",
      "C Tufanaru",
      "A McArthur",
      "E Aromataris"
    ],
    "year": 2018,
    "journal": "BMC Medical Research Methodology",
    "doi": "10.1186/s12874-018-0611-x",
    "citation_key": "munn2018",
    "url": "https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-018-0611-x",
    "content": "This methodological paper provides guidance on choosing between systematic reviews and scoping reviews. Systematic reviews can be broadly defined as a type of research synthesis conducted by review groups with specialized skills who set specific research questions. The selection of review type is wholly dependent on the research question. Systematic reviews address clear and answerable research questions rather than a general topic or problem of interest. The purpose of a scoping review is to provide an overview of available research evidence without producing a summary answer to guide clinical decision-making."
  },
  "khan2003": {
    "id": "khan2003_systematic_steps",
    "title": "Five steps to conducting a systematic review",
    "authors": [
      "KS Khan",
      "R Kunz",
      "J Kleijnen",
      "G Antes"
    ],
    "year": 2003,
    "journal": "Evidence-Based Medicine",
    "doi": "10.1136/ebm.8.2.36",
    "citation_key": "khan2003",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC539417/",
    "content": "This paper provides a step-by-step explanation of the methods behind systematic reviewing, with five key steps: framing the question, identifying relevant work, assessing the quality of studies, summarizing the evidence, and interpreting the findings. Systematic reviews require clear and answerable research questions, and the question needs to be structured using frameworks such as PICO (Patient, Intervention, Comparison, Outcome). The framework helps team members clarify and refine the scope of their question."
  },
  "aldakheel2021": {
    "id": "aldakheel2021_allergic_review",
    "title": "Allergic Diseases: A Comprehensive Review on Risk Factors and Treatment",
    "authors": [
      "FM Aldakheel"
    ],
    "year": 2021,
    "journal": "International Journal of Environmental Research and Public Health",
    "doi": "10.3390/ijerph182111327",
    "citation_key": "aldakheel2021",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8622387/",
    "content": "This article provides an overview of the risk factors and treatment for allergy disorders, as well as the allergy-promoting mechanism of viruses and other environmental factors. The review comprehensively covers allergic diseases including their epidemiological trends, quality of care, and barriers in management. It addresses the scope of allergic disorders by examining multiple manifestations and their interrelationships."
  },
  "nishikawa2022": {
    "id": "nishikawa2022_pico_framework",
    "title": "Research Questions with PICO: A Universal Mnemonic",
    "authors": [
      "A Nishikawa-Pacher"
    ],
    "year": 2022,
    "journal": "Publications",
    "doi": "10.3390/publications10030021",
    "citation_key": "nishikawa2022",
    "url": "https://www.mdpi.com/2304-6775/10/3/21",
    "content": "This paper discusses that a well-formulated research question should incorporate the components of a 'problem', an 'intervention', a 'control', and an 'outcome'—at minimum. The PICO framework is a model commonly used for clinical and healthcare related questions, often used for searching for quantitatively designed studies. The classical evidence-based approach to formulating a question uses the PICO framework, consisting of population, intervention, comparison, and outcome."
  },
  "cumpston2021": {
    "id": "cumpston2021_pico_synthesis",
    "title": "The use of 'PICO for synthesis' and methods for synthesis without meta-analysis",
    "authors": [
      "MS Cumpston",
      "TJ Page",
      "JE McKenzie",
      "J Thomas",
      "MJ Chandler"
    ],
    "year": 2021,
    "journal": "Systematic Reviews",
    "doi": "10.1186/s13643-021-01626-4",
    "citation_key": "cumpston2021",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7919603/",
    "content": "This study examines two intertwined aspects of synthesis that commonly challenge authors of systematic reviews examining the effects of health interventions. It discusses how PICO frameworks can be used for both developing research questions and search strategies. The paper addresses methodological considerations for defining the scope and research questions in systematic reviews."
  },
  "daniel2000": {
    "id": "daniel2000_stat6_sh2",
    "title": "A Gain-of-function Mutation in STAT6",
    "authors": [
      "C Daniel",
      "R Salvekar",
      "U Schindler"
    ],
    "year": 2000,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.275.19.14255",
    "citation_key": "daniel2000",
    "url": "https://pubmed.ncbi.nlm.nih.gov/10747856/",
    "content": "This study identified two amino acids in the STAT6 SH2 domain that, when mutated, uncouple the activity of the STAT6 protein from its regulatory cytokine, IL-4. The STAT6VT mutant carries two amino acid changes in the SH2 domain that affect the overall structure and stability of the monomeric and dimeric protein. The SH2 domain mutations result in constitutive STAT6 activation independent of cytokine stimulation, demonstrating the critical role of the SH2 domain in maintaining proper STAT6 regulation and preventing aberrant allergic responses."
  },
  "litterst2002": {
    "id": "litterst2002_stat6_tad",
    "title": "An LXXLL Motif in the Transactivation Domain of STAT6 Mediates Recruitment of NCoA-1/SRC-1",
    "authors": [
      "CM Litterst",
      "E Kliem",
      "et al"
    ],
    "year": 2002,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.M201831200",
    "citation_key": "litterst2002",
    "url": "https://www.jbc.org/article/S0021-9258(18)36571-2/fulltext",
    "content": "This study identifies an LXXLL motif in the transactivation domain of STAT6 that mediates recruitment of nuclear receptor coactivators NCoA-1/SRC-1. The transactivation domain, located at the C-terminal end of STAT6, contains this conserved motif that is essential for the transcriptional activity of STAT6. The LXXLL motif facilitates interaction with coactivator proteins, enhancing STAT6-mediated gene transcription in allergic responses. This structural feature in the transactivation domain is crucial for the full transcriptional potential of STAT6 in promoting type 2 immune responses and allergic inflammation."
  },
  "mandal2015": {
    "id": "mandal2015_sh2_targeting",
    "title": "Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Small Molecules",
    "authors": [
      "PK Mandal",
      "W Gao",
      "et al"
    ],
    "year": 2015,
    "journal": "Journal of Medicinal Chemistry",
    "doi": "10.1021/acs.jmedchem.5b01265",
    "citation_key": "mandal2015",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5109833/",
    "content": "This study focuses on developing small molecule inhibitors targeting the SH2 domain of STAT6 for allergic airway disease treatment. The SH2 domain is the most functional domain of STAT6, serving two critical purposes: providing a docking domain for binding to phosphorylated tyrosine residues on cytokine receptors and facilitating STAT6 dimerization after phosphorylation. Small molecules that disrupt SH2 domain function can inhibit STAT6 activation, dimerization, and nuclear translocation, thereby blocking the transcription of genes involved in allergic inflammation, including those regulating eosinophil recruitment, IgE production, and airway hyperresponsiveness."
  },
  "zhou2012": {
    "id": "zhou2012_stat6_phosphorylation",
    "title": "STAT6 phosphorylation inhibitors block eotaxin-3 secretion in bronchial epithelial cells",
    "authors": [
      "L Zhou",
      "H Ohkawara",
      "et al"
    ],
    "year": 2012,
    "journal": "Bioorganic & Medicinal Chemistry Letters",
    "doi": "10.1016/j.bmcl.2011.11.029",
    "citation_key": "zhou2012",
    "url": "https://www.sciencedirect.com/science/article/pii/S0968089611010121",
    "content": "This study demonstrates that following binding to receptor phosphotyrosines by its SH2 domain, STAT6 becomes phosphorylated at conserved tyrosine residue Y641 and subsequently dimerizes. The phosphorylation at Y641 is essential for STAT6 activation and function in allergic responses. Inhibitors targeting STAT6 phosphorylation can effectively block the secretion of eotaxin-3 (CCL26), a key chemokine involved in eosinophil recruitment in allergic diseases like asthma. This highlights the importance of the phosphorylation mechanism in STAT6-mediated allergic inflammation."
  }
}